Biodegradable Periodic Mesoporous Organosilica (BPMO) nanomaterials and methods of making BPMOs loaded with Neutron Capture Agents are disclosed herein. Consequently, the BPMOs loaded with Neutron Capture Agents provide a method of treating cancer, immunological disorders and other disease by utilizing a Neutron Capture Therapy modality.

It is an object to provide an imaging method and system. According to an embodiment, an imaging method comprises emitting neutrons into a material, wherein the material converts at least part of the emitted neutrons into a first plurality of gamma ray photons, and wherein at least part of the emitted neutrons pass through the material. Based on the neutrons passed through the material and the gamma ray photons, at least one property of the material can be deduced. An imaging method and an imaging system are provided.

A compound having the structure set forth in Formula (I) and Formula (II): ##STR00001##
wherein the substituents Y, Z, A, B, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.

This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.

The present disclosure describes a method for detecting and treating a low grade malignant tissue in a subject, comprising administering 5-aminolevulinic acid or a pharmaceutically acceptable salt or ester thereof, to the subject and measuring the fluorescence of the tissue.

An interstitial source including a base suitable for implanting in a tumor and alpha emitting atoms attached to the base, with a concentration of at least 6 μCi per centimeter length. The alpha emitting atoms are attached to the base, with a desorption probability upon radioactive decay of not more than 30%.

Various approaches for enhancing treatment of target tissue using a source of focused ultrasound while limiting damage to non-target tissue include selecting a frequency of ultrasound waves transmitted from the source of focused ultrasound for generating a focus in the target tissue; providing microbubbles having the first size distribution such that at least 50% of the microbubbles have a radius smaller than a critical radius corresponding to a resonance frequency matching the selected frequency of ultrasound waves; and applying the ultrasound waves at the selected frequency to treat the target tissue.

The present invention relates to the use of an inhibitor of HER-3 for the treatment of a hyperproliferative disease in combination with radiation treatment.

A method and system for combination therapy utilizing local drug delivery and radiotherapy at a target site of body tissue are provided. The delivery system comprises a source electrode adapted to be positioned proximate to a target site of internal body tissue. A counter electrode is in electrical communication with the source electrode, and is configured to cooperate with the source electrode to form a localized electric field proximate to the target site. A cargo may be delivered to the target site when exposed to the localized electric field. Radiotherapy is applied to the target site in combination with the local drug delivery.

Methods and systems for radiation therapy involve administering a payload/combination of biocompatible high-Z and semiconductor NPs to tissue, such as a tumor or an eye. Ionizing radiation may be directed towards the payload, and ionized electrons generate Cerenkov radiation (CR). The CR interacts with semiconductor NPs to produce chemical species that are damaging to cells. The payload may be administered via injection or via a radiotherapy (RT) device that includes NPs in a biodegradable polymer matrix. Biodegradation of the polymer matrix, which results in release of its payload, may be remotely activated using, for example, electromagnetic or sound waves. The payload may include one or more immunologic adjuvants capable of promoting an immunologic response at remote sites (such as a metastatic tumors) that are separate from the site at which the NPs and adjuvants were administered.